Phase Ib Antibody Drug Conjugate Study in Advanced Platinum-Resistant Ovarian Cancer
Biotech with a promising compound but a highly complex protocol design and a scarcity of comparator arm naïve patients in the U.S.
This trial had been ongoing for 36 months in 10 centers throughout the U.S. Enrollment was slow due to increased competition and a scarcity of eligible patients
The sponsor knew they needed to expand their number of sites outside the U.S. A previous attempt to expand into Canada, using their current provider, proved challenging.
See how Canada’s Experts in Clinical Oncology were able to activate sites in just 13 weeks while a ‘big box’ took over 72 weeks to open a single site in Canada.